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Lymph node status is the most important prognostic factor for women with vulvar, cervical and
endometrial carcinoma and complete lymph node dissection has historically been an integral part
of the surgical treatment of these diseases. Lymphadenectomy can be morbid for patients, who
may experience wound breakdown, lymphocyst formation or chronic lymphedema, among other
problems. Sentinel lymph node mapping is a newer technology that allows selective removal of
the first node draining a tumor thereby allowing a potentially less aggressive procedure to be
performed. Sentinel node mapping is well accepted for the management of breast carcinoma and
cutaneous melanoma, and has resulted in reduced morbidity without adversely affecting
survival. Sentinel node mapping is currently being investigated for treatment of gynecologic
cancers. Recent studies show promise for incorporating the sentinel node mapping technique for
treatment of several gynecologic malignancies.
© 2007 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd.
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The sentinel node is defined as the first node to receive
drainage in a regional node basin. If lymphatic metastasis
occurs from a cancer within a given region, the sentinel node
is the first site of metastasis. Should the sentinel node be
free of metastasis, secondary nodes within the nodal basin
should also be cancer free. Fig. 1 illustrates the concept of
the sentinel node. Sentinel node mapping refers to the
techniques and technologies utilized in the clinical setting toGyn Oncology, University of
st Medical Center Drive, Ann
15 3773; fax: +1 734 764 7261.
K. Reynolds).
07 International Federation ofreliably identify the sentinel node. When the sentinel node is
accurately identified and the histopathology is truly nega-
tive, there is negligible risk of occult metastasis in other
regional lymph nodes. Most importantly, development of
validated sentinel node mapping procedures allows for the
development of selective and less morbid cancer surgery in
contrast to the radical, en block, resection techniques
pioneered by William Halsted in the late 19th century.
The concept of the sentinel node dissection was
pioneered by Cabanas and colleagues in the 1970's [1]. In
a series of 80 patients with penile carcinoma, dorsal
lymphatics were identified using a cut down technique
after injecting blue dye into the penis, and then injecting
contrast into the lymphatic to allow radiological identifica-
tion of the sentinel node. Since then, others have adapted
this technique for other tumors. Morton initially used blueGynecology and Obstetrics. Published by Elsevier Ireland Ltd.
Figure 1 Schematic representation of the sentinel node mapping concept. A tumor is assumed to have a single node that is the first
site of metastatic spread, after which tumor will spread to other, secondary nodes (Illustration supplied by Jordan Mastrodonato).
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reported a true positive rate of 83%, meaning that when
sentinel nodes were removed and compared to the
remaining nodes removed immediately afterward to com-
plete the lymphadenectomy, the sentinel node was always
positive if any other nodes were positive in 83% of cases
thereby indicating the true positive rate [2]. A second
approach, using radiolymphoscintigraphy involves injection
of a radiolabeled colloid that is injected prior to surgery
followed by a nuclear medicine scan to localize nodes. The
surgeon then uses a directional gamma counter to guide
the dissection. The best accuracy has been attained when
both blue dye and radio radiolymphoscintigraphy are
combined.
Several trials have been undertaken including the
Multi-center Selective Lymphadenectomy Trials (MSLT) I
& II for treatment of melanoma. Although these trials are
ongoing, preliminary results from MSLT-I show a significant
survival advantage for patients who underwent wide
excision followed by immediate complete lymph node
dissection for a positive sentinel node biopsy compared to
those who were randomized to wide excision and
observation alone. Sentinel node status was the most
important prognostic factor for 5-year survival in the
group of patients who randomized to sentinel node biopsy.
MSLT-II is comparing the value of complete lymph node
dissection vs. sentinel node biopsy alone in patients with a
positive SLN [3–5].
Sentinel node mapping is now an accepted procedure for
treatment of both breast cancer and cutaneous melanoma.
In a meta-analysis of 69 articles, Kim and colleagues
reported that most institutions performing sentinel node
mapping for breast cancer treatment have “abandoned the
use of completion axillary lymph node dissection in patients
with negative sentinel node biopsy results as experience
and confidence has been gained with lymphatic mapping
and sentinel node biopsy.” In their report, the false
negative rate was found to be inversely proportional to
the number of patients included, showing a median false
negative rate of 7% and illustrating the importance of
experience to the accuracy of the method [6].2. Review of gynecologic experience
The utility of sentinel node mapping is under investigation
for treatment of vulvar, cervical and endometrial carcinoma.
For each of these disease sites, lymph node status is the most
important prognostic factor. Contemporary surgical treat-
ment for each of these diseases involves a complete lymph
node dissection as an integral part of the staging procedure.
The probability of pelvic node metastases in cervical
carcinoma ranges from 4.8% for FIGO stage Ia-2 to 31.4%
for FIGO stage IIB and para-aortic node metastases range
from b1% to 19% for the same stages [7]. For endometrial
carcinoma, the likelihood of positive pelvic nodes range from
2% to 26% for FIGO stage IA grade 1 to stage IB grade 3,
respectively and para-aortic nodes are involved b1% to 16%
for the same stages [8]. For vulvar cancer, if invasion is
b1 mm, the incidence of nodal metastasis is essentially 0%.
This risk increases to 5.4% for 1–2 mm invasion, 8.9% for 2–
3 mm, 25% for 3–4 mm, 28% for 4–5 mm and 32% for N5 mm
invasion [9]. The majority of women with apparent early
stage disease will have a negative metastatic work-up, and
these women will have undergone an extensive surgical
procedure that, in retrospect, was not needed. Most women
therefore derive no benefit from a complete lymph node
dissection for these cancers. With wound infection or
breakdown seen in up to 85% and lymphedema in up to 23%
of women with inguinal node disections, it is appealing to
develop an effective surgical treatment with lower morbidity
[10,11].
3. Vulvar cancer
To date, sentinel node mapping has been most thoroughly
investigated for vulvar carcinoma among the gynecologic
tumors. Over the past few decades, the management of
vulvar carcinoma has progressed toward less radical surgical
intervention, moving away from en bloc radical vulvectomy
to wide local excision or hemivulvectomy with unilateral or
bilateral inguinal lymphadenectomy depending on the
laterality of the tumor. The intent has been to decrease
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breakdown in about 50%, chronic physical or functional
defects in 5–25%, lymphocyst formation in 7–28% and
lymphedema in 7–19% of patients [12,13]. Even with the
less radical procedure, inguinal lymphadenectomy still
accounts for most of the perioperative morbidity. In 1978,
Disaia proposed replacing the complete inguino-femoral
dissection with a superficial inguinal lymphadenectomy,
stating that femoral nodes should not be positive if
metastases were found to be absent in the superficial
nodes. Unfortunately, patients treated in this fashion
experienced an unexpectedly high incidence of groin
recurrence [14–17]. In 1994, Levenback published experi-
ence with sentinel node mapping for vulvar cancer using blue
dye injection. A subsequent update of this study in 2001
documented accurate identification of the sentinel node in
88% of patients and 75% of groins dissected. No false
negatives were reported, but a sentinel node was not
identified in 2 patients. Their conclusions were that in
properly selected patients, blue dye alone could identify the
sentinel node in 95% of patients. Three reported risk factors
for failure included midline location of the tumor, previous
excisional biopsy and inexperience of the surgeon [18,19].
Ansink published experience with a similar technique but
with less impressive results. Using blue dye injection, the
sentinel node was found in only 56% of the 93 groins dissected
and two false negatives were reported [20]. Others have
noted more accurate detection rates using radiolymphoscin-
tigraphy alone or in combination with blue dye injection.
Following Decesare's initial 1997 report using injections of
99mTc-labeled colloid, multiple studies have confirmed the
utility and feasibility of radiolymphoscintigraphy for vulvar
cancer [21]. In a review of more than twenty studies
published over the last 12 years, a total of 5 false negative
sentinel nodes have been reported in nearly 450 patients and
700 groin dissections. Accurate sentinel node detection rates
range from 66–100% for either blue dye or radiolymphoscin-
tigraphy, and 91–100% if radiolymphoscintigraphy is included
in the assessment. All five of the false negative studies were
found in three studies: in two of the studies, the case
experience of the surgeons was small (b25 patients) and in
one, only blue dye was used [20,22,23]. A few case reports
exist in the literature describing true false negative sentinel
nodes with positive nodes found distally [22,24,25]. There
are no published randomized clinical trials to assess the role
of sentinel node mapping for vulvar cancer. The Gynecologic
Oncology Group has a large, prospective trial to assess
sentinel node mapping for vulvar cancer that is currently
accruing patients.4. Cervical cancer
Radical hysterectomy with pelvic lymphadenectomy is a
preferred treatment for early-stage, macroscopic cervical
cancer. Significant postoperative morbidity includes lym-
phocyst formation, lymphedema, bladder dysfunction and
nerve damage, all of which are at least partially associated
with the lymphadenectomy. Morbidity is further exacerbated
if postoperative radiation is employed.
Since the first published report by Echt in 1999 using blue
dye sentinel node mapping for cervical cancer, bothexperience and success with the procedure have expanded
considerably. The initial accurate detection rate was 23% and
has since improved to a range of 80–100% when dual
detection techniques were utilized with a false negative
rate of 10% or lower [26].
Bats has reported an 87% accurate detection rate using
both blue dye and radiolymphoscintigraphy for 25 patients
with cervical cancer. The reported accuracy rate for blue dye
alone was 83.3% compared to 75% for radiolymphoscintigra-
phy. The majority of sentinel nodes were found in the inter-
iliac regions, as expected. Of note, in 9 patients (36%), the
sentinel node was identified in an ‘unusual location’ outside
of the inter-iliac area including the common iliac node region
in 5 patients, parametrium in 2 patients and para-aortic
nodes in 2 patients. These findings support their hypothesis
that sentinel node mapping may improve the management of
early cervical carcinoma by detecting metastasis in nodes
that are not routinely removed [27].5. Endometrial cancer
Sentinel node mapping of endometrial carcinoma has proven
to be more problematic to develop for several reasons. First,
the lymphatic drainage of the uterus is considerably more
ambiguous than vulva and cervix. Second, the more focal,
accessible and visible lesions that occur on the vulva or cervix
are amenable to directed injection whereas endometrial
lesions are often large and are always both inaccessible and
not visible to the clinician for direct injection. The reported
locations of sentinel nodes range from the parametrium to
the para-aortic region on either side of the body. Interpreting
the literature has also been complicated by the lack of
standardization of injection sites. Injection sites reported
include subserosal, myometrium, cervical stroma, transcer-
vical myometrium and hysteroscopically-directed injection
of endometrium. Fundal and cervical injection sites map the
drainage basin of that specific segment of the uterus, but not
necessarily of the tumor itself. Frumovitz states in the
discussion of their recent experience with 18 women under-
going fundal injections for endometrial cancer that the
injections map ‘the organ rather than the cancer [28].’
An additional limitation is the timing of the injection. If
the injection is to be at the fundus of the uterus, this is an
intra-operative procedure in contrast to vulvar and cervical
mapping where injection of the radiocolloid typically takes
place 2–24 h prior to surgery thereby allowing time for
collection in the nodes and subsequent imaging. Intra-
operative fundal injection shortens the drainage time to
minutes and could reduce the sensitivity of the test.
In studies where only blue dye was used, erratic sentinel
node detection rates ranging from 0% to 100% have been
reported. With the addition of radiocolloid injection,
detection rates are consistently above 70%. Using a
combined blue dye and radiocolloid injection technique,
Frumovitz reported an accurate detection rate of 31%, with
an increase to 80% when surgeons without experience with
the procedure were excluded. Several studies have exam-
ined the use of pre-operative hysteroscopically-guided
injection of the endometrium. Detection rates in these
studies range from 82% to 100%. Both Maccauro and Niikura
confirmed that lymphatic drainage pathways of the cervix
Table 1 Example protocol for combined blue dye and
radiolymphoscintigrapghy for vulvar cancer [18,36,37]
• Both radiolymphoscintigraphy and blue dye are used to
localize the sentinel node
• The radiocolloid used is technetium 99 (450 μCi 99mTc)
sulfur colloid (filtered to 0.2 μm) is injected intradermally
in 4 sites at the periphery of the tumor 2–4 h pre-op
• Gamma scan is performed (see Fig. 2) and sentinel node(s)
is marked
• Films are brought with the patient to the OR
• At beginning of surgical procedure, 4–8 ml of 1% isosulfan
blue dye is injected intradermally at 4 sites around the
periphery of the tumor
• Incision is made over the sentinel node determined by
lymphoscintigraphy
• Hand held gamma probe assists in localization of node(s)
• Blue dye is located (see Fig. 3)
• No further nodes are removed unless hand held probe
identifies a second node(s) with N10% of the sentinel node
activity or N150% of background activity
• Specimen is submitted for special processing per protocol,
but NOT frozen section
• If biopsy is positive, full lymphadenectomy may be
warranted depending on the clinical protocol
Figure 2 Radiolymphoscintigram showing ‘hot’ nodes. The
center of the image is blocked to prevent washout of the image
by the high level of radioactivity at the site of injection on the
vulva. This image is utilized by the surgeon to plan the site of
incisions in order to minimize the extent of the dissection.
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increased likelihood of para-aortic sentinel nodes associated
with the uterine corpus [29,30]. This confirms the increased
likelihood of false negative sentinel nodes if only the cervix is
injected for endometrial cancers. A potential concern of this
technique is intra-abdominal dissemination of tumor during
hysteroscopy due to intrauterine distension and retrograde
spill through the Fallopian tubes. Niikura addresses this issue
by using only 40 mm Hg for uterine distension which is less
than the 70 mm Hg usually needed for tubal distension.
Second, hysteroscopy was performed on the day of definitive
surgery, thereby decreasing the time for possible extruded
cells to remain in the abdomen prior to irrigation. Niikura
reported one case of positive cytology and no intraperitoneal
spillage of blue dye was noted in any patient.
6. Technique
A number of methods have been reported for blue dye and
radiolymphoscintigraphy techniques. Typically, a blue dye, a
radiocolloid, or both, is injected into the tissue surrounding
the tumor. Blue dyes used include either patent blue or
isosulfan blue. The radioactive tracers most often used are
either Technetium-99m labeled albumin or sulfur colloid.
Radiocolloid is injected usually 2–4 h preoperatively if 99mTc
sulfur colloid is used and on pre-op day 1 if 99mTc albumin is
used, although a number of protocol variations have been
reported. Vulvar lesions are typically injected at the junction
of the tumor and normal skin in varying patterns, often
dependent upon the location of the lesion. In cases of
cervical malignancy, the cervical stroma is injected circum-
ferentially. Peri-tumoral injection is preferred, as it should
allow the tracer to follow the same path as the lymphatic
drainage of the lesion itself. In the case of endometrial
carcinomas the site(s) of injection are not as well defined. Ifa radioisotope is employed, a preoperative radiolymphos-
cintigram is performed on either the day prior to or the day
of surgery to aid in localization of the sentinel node(s). For
patients with vulvar cancer, the skin overlying the sentinel
node is marked using the radiolymphoscintigram, allowing
for smaller, more selective incisions. Blue dye injection
typically takes place immediately prior to surgical incision.
Table 1 provides a typical protocol for combined blue dye and
radiolymphoscintigraphy.
In the operating room, dissection of the sentinel node is
performed first in most cases. In vulvar procedures using the
combined blue dye and radiolymphoscintigraphy technique,
the superficial inguinal nodes are examined with a handheld,
directional gamma probe prior to and after incision to guide
dissection in conjunction with visual inspection for the
presence of blue lymphatic channels and nodes after the
incision is made. If a preoperative radiolymphoscintigram
was performed, this image is used to guide the site and size
of the incision and to localize the sentinel node. In cases of
cervical or endometrial carcinoma, the lymphatic evaluation
Figure 3 Photograph of sentinel node displaying uptake of blue
dye. The blue color, either alone, or in conjunction with use of
radiocolloid injection and radiolymphoscintography, allows the
surgeon to identify the sentinel nodewhich can then be selectively
excised.
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or laparotomy. A laparoscopic gamma probe is employed for
the minimally invasive procedures. Once the sentinel node is
localized and excised with as little disruption as possible to
surrounding tissues, the directional gamma counter is used to
assess for background radiation that indicates if the correct
node has been removed or if there is another sentinel node.
The background radiation count should not exceed 10% of the
count from the sentinel node. Nodes are usually re-examined
with the probe ex vivo to confirm radioactivity, and the
lymphadenectomy site is reassessed to exclude residual
radioactivity. Sentinel nodes are then sent for pathological
evaluation as separate specimens.
7. Pathology
The histopathologic examination of a sentinel node is a
crucial step for accurate diagnosis and the results will dictate
if further surgical intervention such as completion lympha-
denectomy is necessary. Frozen sectionwas originally favored
as the determinant of whether completion lymphadenectomy
was warranted. However, false negative rates as high as 70%
were reported for frozen sections, and this step has been
omitted from sentinel node evaluation in most centers.
Typically, routine paraffin embedding and hematoxylin and
eosin staining is performed. In cases with micrometastases,
serial step sectioning and immunohistochemistry studies
specific to the tumor type have been reported to greatly
increase accuracy of diagnosis and to minimize the likelihood
of a false negative report. This technique has resulted in an
increase in rate of positive node detection reported in a
number of studies [31–35]. De Hullu was one of the first to
publish experience with ultrastaging in 59 patients with
vulvar carcinoma. This technique detected 4 additional
metastatic lymph nodes out of 102 (4%) originally found to
be negative on routine histological examination. A number of
authors have reported similar findings, with increases in the
node positivity rate of up to 5.1%.8. Conclusion
The presence of lymph node metastasis remains the most
important prognostic factor for women with vulvar, cervical
and endometrial carcinoma, but complete lymphadenectomy
for these patients can be morbid and costly. The ability to
detect the presence of lymphatic tumor spread by accurately
assessing the sentinel node in the lymphatic drainage basin
has been shown to be feasible for many cancer types,
including vulvar and cervical cancers, and is under develop-
ment for endometrial cancer. Once prospective studies have
been completed to assess for differences in outcome,
sentinel node mapping will allow for selective removal of
nodes at risk, while sparing other nodes and reducing
operative morbidity substantially. Sentinel node mapping is
already accepted for the management of breast cancer and
cutaneous melanoma. For gynecologic cancers, the results
are promising, particularly for vulvar cancer. Until any of
several large, ongoing, multicenter trials are completed, this
technological advancement will be considered promising, but
not yet a standard of care for treatment of women with
gynecologicmalignancies. Given the collective interest in the
less morbid treatment for patients with cancer, sentinel node
mapping deserves continued development.References
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